Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
2 ^USD	-0.99%		-11.11%	+56.25%

09/05	Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	CI

Regulus Therapeutics Inc. Elects Bruce L.A. Carter, Mark G. Foletta, William Rastetter and Douglas Williams as Directors

June 13, 2013 at 01:36 am IST

Regulus Therapeutics Inc. announced at the AGM held on June 10, 2013, the shareholders elected Bruce L.A. Carter, Ph.D., Mark G. Foletta, William Rastetter, Ph.D. and Douglas Williams, Ph.D as directors, each to serve until the company's 2014 Annual Meeting of Stockholders and until their successors are duly elected and qualified.

Latest news about Regulus Therapeutics Inc.

Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	06/05	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03	CI
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating	19/03	MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target	18/03	MT
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors	14/03	CI
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating	13/03	MT
Top Midday Gainers	12/03	MT
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	12/03	MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	12/03	MT
Transcript : Regulus Therapeutics Inc. - Special Call	12/03
Top Premarket Gainers	12/03	MT
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	12/03	CI
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors	11/03	CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	03/01	CI
Transcript : Regulus Therapeutics Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:25 AM	29/11
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Top Premarket Decliners	09/11	MT
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	02/11	CI
Canaccord Genuity Raises Regulus Therapeutics' Price Target to $12 From $9, Keeps Buy Rating	21/23/21	MT
Transcript : Regulus Therapeutics Inc. - Special Call	20/23/20
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	13/23/13	CI
Transcript : Regulus Therapeutics Inc. - Special Call	06/23/06
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI

Chart Regulus Therapeutics Inc.

Duration

Period

More charts

Company Profile

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2 USD

Average target price

7.25 USD

Spread / Average Target

+262.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGULUS THERAPEUTICS INC.	+56.25%	13Cr
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	11TCr
REGENERON PHARMACEUTICALS, INC.	+10.21%	10TCr
ARGENX SE	+0.41%	2.23TCr
BIONTECH SE	-11.90%	2.24TCr
GENMAB A/S	-5.99%	1.91TCr
WUXI APPTEC CO., LTD.	-37.36%	1.8TCr
BEIGENE, LTD.	-5.17%	1.79TCr
NEUROCRINE BIOSCIENCES, INC.	+7.70%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+37.65%	1.25TCr

Bio Therapeutic Drugs